Want to see DE:AJ91 full AI Analyst Report?
Top Page
DocCheck AG
(XETRA:AJ91)
Select Model
Select Model
Rating:63Neutral
Price Target:
€11.50
▼(-0.86% Downside)
Action:Reiterated
Date:08/22/26
The score is driven primarily by solid financial stability (low leverage and healthy equity base) but tempered by weaker operating momentum and inconsistent cash-flow conversion. Valuation is a meaningful positive (moderate P/E and high dividend yield), while technical indicators are clearly bearish with the stock trading below key moving averages and negative MACD.
Positive Factors
Conservative Balance Sheet
Low leverage and a strong equity base reduce financial risk and preserve flexibility for investment, dividends, or resilience if healthcare-sector marketing demand weakens.
Negative Factors
Weak Revenue Trajectory
Recent revenue contraction indicates weaker demand or execution momentum, limiting operating leverage and making sustained earnings growth less dependable over the next several reporting periods.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Low leverage and a strong equity base reduce financial risk and preserve flexibility for investment, dividends, or resilience if healthcare-sector marketing demand weakens.
Read all positive factors
DocCheck AG (AJ91) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€55.30M
Dividend Yield9.17%
Average Volume (3M)1.04K
Price to Earnings (P/E)10.4
Beta (1Y)0.56
Revenue Growth2.84%
EPS Growth0.96%
CountryDE
Employees414
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)1.05
Shares Outstanding5,073,816
10 Day Avg. Volume577
30 Day Avg. Volume1,041
Financial Highlights & Ratios
PEG Ratio12.18
Price to Book (P/B)1.50
Price to Sales (P/S)1.13
P/FCF Ratio23.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
DocCheck AG Business Overview & Revenue Model
Company Description
DocCheck AG offers community, agency, and e-commerce services for the healthcare sector in Europe. The company develops and implements communication strategies for media on healthcare and business-to-business sectors; sells medical supplies and me...
How the Company Makes Money
DocCheck AG primarily generates revenue by selling digital marketing, communication, and related online services to customers in the healthcare and life-sciences industry, using its healthcare-professional-focused online environment and audience a...
DocCheck AG Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
78
Positive
Cash Flow
55
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 55.32M | 53.79M | 53.41M | 60.90M | 85.92M |
| Gross Profit | 12.28M | 10.53M | 12.97M | 14.08M | 21.54M |
| EBITDA | 10.39M | 10.18M | 9.38M | 13.38M | 20.09M |
| Net Income | 5.33M | 5.28M | 2.27M | 6.29M | 11.40M |
Balance Sheet | |||||
| Total Assets | 55.68M | 60.86M | 56.14M | 63.28M | 60.25M |
| Cash, Cash Equivalents and Short-Term Investments | 18.54M | 21.02M | 17.52M | 15.66M | 21.52M |
| Total Debt | 4.16M | 5.01M | 5.85M | 7.07M | 7.03M |
| Total Liabilities | 14.07M | 20.78M | 18.11M | 23.86M | 22.08M |
| Stockholders Equity | 41.61M | 40.08M | 37.33M | 38.57M | 37.31M |
Cash Flow | |||||
| Free Cash Flow | 2.61M | 6.82M | 5.62M | -557.91K | 6.90M |
| Operating Cash Flow | 6.14M | 7.82M | 7.51M | 5.89M | 10.92M |
| Investing Cash Flow | -3.81M | -1.48M | -1.93M | -4.92M | -4.39M |
| Financing Cash Flow | -4.88M | -3.50M | -4.60M | -5.81M | -5.86M |
DocCheck AG Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | €43.32M | 19.67 | 12.34% | 3.93% | -6.92% | -67.82% | |
63 Neutral | €55.30M | 10.38 | 13.28% | 8.70% | 2.84% | 0.96% | |
55 Neutral | €278.52M | 24.77 | 2.16% | ― | 9.88% | -38.44% | |
53 Neutral | €1.45B | 43.42 | 4.19% | 1.82% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
DE:AJ91
DocCheck AG
10.90
-0.31
-2.77%
DE:COP
CompuGroup Medical
27.00
3.93
17.06%
DE:M3V
MeVis Medical Solutions
23.80
-0.10
-0.42%
DE:ILM1
Medios AG
10.90
-3.92
-26.45%
DE:MDQ
MediNavi AG
3.90
-0.10
-2.50%
DE:5NB
Novetum AG
40.00
11.40
39.86%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.